Dr. Lugtenburg on Maintenance Rituximab in DLBCL

Pieternella J. Lugtenburg, MD, PhD
Published: Thursday, Jun 20, 2019



Pieternella J. Lugtenburg, MD, PhD, an internist and hematologist at Erasmus Medical Center in Rottenham, Netherlands, discusses the use of rituximab (Rituxan) as maintenance therapy in patients with diffuse large B-cell lymphoma (DLBCL).

Options are expanding for patients with DLBCL, however discovering therapies to extend survival for those patients who achieve complete remission (CR) remains a challenge with 40% of patients still having relapsed or refractory disease after rituximab is added to CHOP, says Lugtenburg.

In the second randomization of a phase II study, investigators evaluated rituximab as maintenance therapy versus observation for patients who achieved CR after R-CHOP. At median follow up of 79.9 months, the 5‐year DFS rate was 79% with rituximab maintenance versus 74% with observation (HR, 0.83; 95% CI, 0.57‐1.19; P = 0.31), showing no statistically significant benefit with rituximab. Investigators could not identify another subgroup of patients who benefitted from maintenance therapy in the study, Lugtenberg concludes.

<<< 15th International Conference on Malignant Lymphoma


Pieternella J. Lugtenburg, MD, PhD, an internist and hematologist at Erasmus Medical Center in Rottenham, Netherlands, discusses the use of rituximab (Rituxan) as maintenance therapy in patients with diffuse large B-cell lymphoma (DLBCL).

Options are expanding for patients with DLBCL, however discovering therapies to extend survival for those patients who achieve complete remission (CR) remains a challenge with 40% of patients still having relapsed or refractory disease after rituximab is added to CHOP, says Lugtenburg.

In the second randomization of a phase II study, investigators evaluated rituximab as maintenance therapy versus observation for patients who achieved CR after R-CHOP. At median follow up of 79.9 months, the 5‐year DFS rate was 79% with rituximab maintenance versus 74% with observation (HR, 0.83; 95% CI, 0.57‐1.19; P = 0.31), showing no statistically significant benefit with rituximab. Investigators could not identify another subgroup of patients who benefitted from maintenance therapy in the study, Lugtenberg concludes.

<<< 15th International Conference on Malignant Lymphoma

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x